The licensing part is music to my ears. I’m glad
Post# of 72440
Which BP with oncology pipeline wouldn’t want to add B-OM? Not only they could make money in a $1B market with little competition, they could also sell more cancer drugs because patients don’t need to discontinue their treatments due to severe OM.